Simoctocog alfa
Nuwiq, Vihuma (simoctocog alfa) is a protein pharmaceutical. Simoctocog alfa was first approved as Nuwiq on 2014-07-22. It is used to treat factor VII deficiency, hemophilia a, hemorrhage, and von willebrand diseases in the USA. It has been approved in Europe to treat hemophilia a.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| factor vii deficiency | — | D005168 | D68.2 |
| hemophilia a | EFO_0007267 | D006467 | D66 |
| hemorrhage | MP_0001914 | D006470 | R58 |
| von willebrand diseases | Orphanet_903 | D014842 | D68.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
83 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 9 | 3 | 26 | 12 | 29 | 77 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | 1 | 1 | 2 | 4 |
| Von willebrand diseases | D014842 | D68.0 | — | 1 | 1 | 1 | — | 3 | |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | 1 | 1 | 3 |
| Hemophilia b | D002836 | D67 | — | — | 1 | 1 | — | 2 | |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | 1 | 1 | 2 |
| Blood platelet disorders | D001791 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Joint diseases | D007592 | HP_0003040 | M12.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SIMOCTOCOG ALFA |
| INN | simoctocog alfa |
| Description | Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII. Certain preparations may also be used in those with von Willebrand's disease. It is given by slow injection into a vein.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 139076-62-3 |
| RxCUI | 1300486 |
| ChEMBL ID | CHEMBL2108319 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00025 |
| UNII ID | U50VWW6XH6 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more